|
|
Vaccine Detail
|
HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) |
| Vaccine Information |
- Vaccine Name: HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)
- Target Pathogen: Human Immunodeficiency Virus
- Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
- Vaccine Ontology ID: VO_0004344
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Macaque
- gag
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- pol
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- env
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- tat
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- rev
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- vif
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- vpr
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- vpu
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000258
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Macaque Response
- Vaccine Immune Response Type: VO_0000286
- Immune Response: Co-delivery of GM-CSF and vaccine DNAs enhanced the temporal appearance of neutralizing Ab and broadened the specificity of the neutralizing activity to include SHIV-89.6P (Robinson et al., 2006).
- Efficacy: The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-adjuvanted group. After 52 weeks, the non-GM-CSF group continued to show some peaks of re-emergent virus whereas the GM-CSF group continued to maintain control below our level of detection (Robinson et al., 2006).
|
| References |
Robinson et al., 2006: Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology. 2006; 352(2); 285-294. [PubMed: 16740288].
|
|
